Drug Profile
Exenatide - Oramed Pharmaceuticals
Alternative Names: Oral GLP-1 analog capsule - Oramed; Oral Glucagon-like peptide-1 analog capsule - Oramed; ORMD-0901; ORMD-901Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Oramed Pharmaceuticals
- Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in USA (PO, Capsule)
- 27 Jan 2021 Exenatide oral - Oramed Pharmaceuticals is available for licensing as of 27 Jan 2021. https://www.oramed.com/contact-us/
- 27 Jan 2021 Oramed plans a phase II trial for Type-2 diabetes mellitus in USA, in 2021